Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Combined With Paclitaxol in Advanced Gastric Cancer With Peritoneal Metastasis
NCT03144843Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Rivoceranib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 1 year. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03144843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03144843.